Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Oct 1, 2026 · Filed Oct 6, 2026
Belite Bio's Chief Medical Officer sold $2K of Belite Bio shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$2,019
Shares × reported transaction price
Closed at $162.98 on Oct 1, 2026, 109% above its 52-week low and 16% below its high, after a 3% drop over the previous 30 trading days
52-week range $78.06 (Oct 8, 2025) to $193.61 (Sep 4, 2026), 73% of the way up, from 246 adjusted closes. 30 trading days earlier: $168.55 on Aug 19, 2026. Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −2.4% | −0.1% | −2.3% |
| 30 days | −8.0% | −5.9% | −2.1% |
Past results only. Not a forecast.
Insider filing
Traded Sep 24 · filed 37 days later
Derivative exercise or conversion — not an open-market buy.
Insider filing
Traded Sep 24 · filed 37 days later
Derivative exercise or conversion — not an open-market buy.
Insider filing
Traded Oct 29 · filed 2 days later
Not classified as an open-market trade.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.